<生产厂家价格>

盐酸奈必洛尔

盐酸奈必洛尔用途

Nebivolol盐酸盐是β1- 肾上腺素受体选择性抑制剂,IC50为0.8 nM。

盐酸奈必洛尔名称

[ CAS 号 ]:
152520-56-4

[ 中文名 ]:
奈比洛尔盐酸盐

[ 英文名 ]:
Nebivolol hydrochloride

[中文别名 ]:

[英文别名 ]:

(S,R,R,R)-nebivolol hydrochloride
Nebivolol hydrochloride

盐酸奈必洛尔生物活性

[ 描述 ]:

Nebivolol盐酸盐是β1- 肾上腺素受体选择性抑制剂,IC50为0.8 nM。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 肾上腺素能受体

研究领域 >> 心血管疾病

[参考文献]

[1]. Brehm BR, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001 Feb 1;49(2):430-9.

[2]. Mercanoglu G, et al. The effects of nebivolol on apoptosis in a rat infarct model. Circ J. 2008 Apr;72(4):660-70.

[相关活性小分子]

盐酸奈必洛尔物理化学性质

[ 沸点 ]:
600.5ºC at 760 mmHg

[ 熔点 ]:
220-222ºC

[ 分子式 ]:
C₂₂H₂₆ClF₂NO₄

[ 分子量 ]:
441.896

[ 闪点 ]:
316.9ºC

[ 精确质量 ]:
441.151855

[ PSA ]:
70.95000

[ LogP ]:
3.55650

[ 外观性状 ]:
白色至灰白色粉末

[ 蒸汽压 ]:
2.88E-15mmHg at 25°C

[ 储存条件 ]:
Desiccate at RT

[ 水溶解性 ]:
DMSO: ≥20mg/mL

盐酸奈必洛尔MSDS

详细MSDS(安全技术说明书)

盐酸奈必洛尔安全信息

[ 符号 ]:

GHS07, GHS09

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302-H410

[ 警示性声明 ]:
P273-P501

[ 危害码 (欧洲) ]:
Xn,N

[ 风险声明 (欧洲) ]:
22-50/53

[ 安全声明 (欧洲) ]:
60-61

[ 危险品运输编码 ]:
3077

[ 海关编码 ]:
2932999099

盐酸奈必洛尔海关

[ 海关编码 ]: 2932999099

[ 中文概述 ]:
2932999099. 其他仅含氧杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

盐酸奈必洛尔文献

Design, development and permeation studies of nebivolol hydrochloride from novel matrix type transdermal patches.

Adv. Biomed. Res. 2 , 62, (2013)

Nebivolol hydrochloride is a third generation β-blocker with highly selective β1-receptor antagonist with antihypertensive properties having plasma half life of 10 h and 12% oral bioavailability. The ...

Simultaneous estimation of amlodipine besylate and nebivolol hydrochloride in tablet dosage forms by reverse phase-high-performance liquid chromatographic using ultraviolet detection.

Pharm. Methods 2 , 9-14, (2013)

The present study aimed to develop and validate the simultaneous estimation of amlodipine and nebivolol in tablet dosage forms.An isocratic reversed phase high-performance liquid chromatographic (HPLC...

Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.

FASEB J. 25 , 4486-97, (2011)

β-Adrenoceptor antagonists differ in their degree of partial agonism. In vitro assays have provided information on ligand affinity, selectivity, and intrinsic efficacy. However, the extent to which th...

更多文献